Financial News

Recent Quotes
My Watchlist
Indicators
Motherlode Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Albireo Pharma Inc (NQ: ALBO )

36.07 USD +0.30 (+0.84%)
Streaming Delayed Price Updated: 9:40 AM EST, Mar 3, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Albireo Pharma Inc

< Previous 1 2 3 4 5 Next >
Albireo Announces Launch of “PFIC Voices”
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the launch of PFIC Voices, a new global campaign to... 
From GlobeNewswire News Releases
Data on Albireo’s Odevixibat Presented at 2019 European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting
Data support further study of odevixibat across a range of rare cholestatic liver diseases 
From GlobeNewswire News Releases
Albireo to Present at Investor Conferences in June
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive... 
From GlobeNewswire News Releases
Albireo Announces Data on Pediatric Cholestatic Liver Diseases to be Presented at the 2019 ESPGHAN Annual Meeting
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that clinical data and important findings from... 
From GlobeNewswire News Releases
Life Science Cares Announces Inaugural Group of Founding Corporate Members
Twenty-seven life science companies have signed on as Founding Members of Life Science Cares, a non-profit collective effort of the Life Science industry to eliminate the impact of poverty in the... 
From Business Wire News Releases
Albireo Reports First Quarter 2019 Financial Results
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced financial results and corporate highlights for the... 
From GlobeNewswire News Releases
Albireo to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live... 
From GlobeNewswire News Releases
New Research: Key Drivers of Growth for CBRE Group, Brookfield Asset Management, Zebra Technologies, Trex, Catalyst Biosciences, and Albireo Pharma — Factors of Influence, Major Initiatives and Sustai
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CBRE Group, Inc.... 
From GlobeNewswire News Releases
Albireo Presents Data on A4250 in Children with Biliary Atresia and Alagille Syndrome at The International Liver Congress 2019
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that results in Alagille syndrome and biliary atresia... 
From GlobeNewswire News Releases
Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that its Investigational New Drug application (IND)... 
From GlobeNewswire News Releases
Albireo to Present at Investor Conferences in April
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will present at the following... 
From GlobeNewswire News Releases
Albireo to Present Clinical Data on A4250 in Alagille Syndrome and Biliary Atresia at The International Liver Congress™ 2019
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that results from its completed Phase 2 clinical... 
From GlobeNewswire News Releases
Albireo Expands Executive Leadership Team with Appointment of Pamela Stephenson as Chief Commercial Officer
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the appointment of Pamela Stephenson, MPH, as Chief... 
From GlobeNewswire News Releases
Avillion Appoints Dr David Chiswell OBE as Board Member
Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates from proof-of-concept through to regulatory approval, today announces the appointment... 
From PR Newswire
Albireo Reports Year-End 2018 Financial Results and Provides Pipeline Update
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced financial results and corporate highlights for the... 
From GlobeNewswire News Releases
Albireo to Present at Cowen and Company 39th Annual Health Care Conference
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive... 
From GlobeNewswire News Releases
Albireo Recognizes Rare Disease Day and Highlights Urgent Need to Support Families Affected by Progressive Familial Intrahepatic Cholestasis (PFIC)
Advances in research and efforts to build awareness of life-threatening, rare, pediatric liver disease offer new hope for patients and families 
From GlobeNewswire News Releases
Albireo to Report Year-End 2018 Financial Results and Host Conference Call and Webcast on March 7, 2019
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live... 
From GlobeNewswire News Releases
New Research Coverage Highlights Starbucks, Cheetah Mobile, Seagate Technology, Momo, Albireo Pharma, and Essent Group — Consolidated Revenues, Company Growth, and Expectations for 2019
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Starbucks Corporation... 
From GlobeNewswire News Releases
Albireo Granted Orphan Drug Designation by FDA For Lead Product Candidate A4250 for Treatment of Biliary Atresia
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the U.S. Food and Drug Administration (FDA) has... 
From GlobeNewswire News Releases
Albireo Granted Orphan Designation by European Commission For Lead Product Candidate A4250 for Treatment of Biliary Atresia
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the European Commission has granted orphan... 
From GlobeNewswire News Releases
Albireo Reports Third Quarter 2018 Financial Results
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced financial results and corporate highlights for the... 
From GlobeNewswire News Releases
Albireo to Present at Investor Conferences in November
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive... 
From GlobeNewswire News Releases
Albireo to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 13, 2018
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that its third quarter financial results will be... 
From GlobeNewswire News Releases
Report: Exploring Fundamental Drivers Behind Manulife Financial, Baozun, AstraZeneca, Insight Enterprises, Albireo Pharma, and Mobile TeleSystems OJSC — New Horizons, Emerging Trends, and Upcoming Dev
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Manulife Financial Corp... 
From GlobeNewswire News Releases
Albireo Granted Orphan Drug Designation For Lead Product Candidate A4250 for Treatment of Alagille Syndrome
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the U.S. Food and Drug Administration (FDA) has... 
From GlobeNewswire News Releases
Albireo Receives FDA Fast Track Designation for A4250
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the U.S. Food and Drug Administration (FDA) has... 
From GlobeNewswire News Releases
Albireo Announces Research on Cholestatic Liver Diseases to be Presented at Major North American Liver Meetings
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that important findings from multiple studies on... 
From GlobeNewswire News Releases
Albireo Appoints Simon Harford as Chief Financial Officer and Treasurer
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the appointment of Simon Harford as Chief Financial... 
From GlobeNewswire News Releases
Factors of Influence in 2018, Key Indicators and Opportunity within Pentair plc, Albireo Pharma, Cardlytics, New Oriental Education & Technology Group, State Street, and Axis Capital — New Research Em
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Pentair plc (NYSE:PNR),... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback